- Zacks
Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 54.55% and 88.87%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates
Agios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark, revenues from its sole marketed drug, Pyrukynd, rise sequentially and on a yearly basis.
- Zacks
Jazz (JAZZ) Q1 Earnings & Sales Fall Short of Estimates
Jazz's (JAZZ) first-quarter earnings and sales miss the mark. The company reaffirms its guidance for full-year 2024.
